Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1971 1
1974 2
1975 6
1976 4
1977 6
1978 2
1979 3
1980 2
1981 2
1983 2
1984 2
1985 1
1988 1
1990 2
1991 1
1992 1
1993 1
1994 1
1995 1
1996 3
1997 1
1999 1
2000 1
2001 2
2002 1
2003 5
2004 4
2005 4
2006 7
2007 5
2008 4
2010 3
2011 3
2012 6
2013 3
2014 4
2015 7
2016 10
2017 6
2018 6
2019 3
2020 6
2021 7
2022 8
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators. Schüpke S, et al. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475799 Clinical Trial.
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Spicka I, et al. Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18. Eur J Haematol. 2022. PMID: 35871357 Free PMC article.
A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. ...
A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethas …
Diabetic Foot Syndrome.
Morbach S, Lobmann R, Eckhard M, Müller E, Reike H, Risse A, Rümenapf G, Spraul M. Morbach S, et al. Exp Clin Endocrinol Diabetes. 2021 Aug;129(S 01):S82-S90. doi: 10.1055/a-1284-6412. Epub 2020 Dec 22. Exp Clin Endocrinol Diabetes. 2021. PMID: 33352597 No abstract available.
Diabetic Foot Syndrome.
Morbach S, Eckhard M, Lobmann R, Müller E, Reike H, Risse A, Rümenapf G, Spraul M. Morbach S, et al. Exp Clin Endocrinol Diabetes. 2023 Feb;131(1-02):84-93. doi: 10.1055/a-1946-3838. Epub 2023 Jan 31. Exp Clin Endocrinol Diabetes. 2023. PMID: 36720238 No abstract available.
Unexpected Cause of Bleeding.
Dufrost V, Risse J, Malgras A, Barraud H, Jaussaud R, Zuily S, Wahl D. Dufrost V, et al. Am J Med. 2017 Sep;130(9):e387-e388. doi: 10.1016/j.amjmed.2017.03.016. Epub 2017 Apr 4. Am J Med. 2017. PMID: 28389311 No abstract available.
Highly infectious prions are not directly neurotoxic.
Benilova I, Reilly M, Terry C, Wenborn A, Schmidt C, Marinho AT, Risse E, Al-Doujaily H, Wiggins De Oliveira M, Sandberg MK, Wadsworth JDF, Jat PS, Collinge J. Benilova I, et al. Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23815-23822. doi: 10.1073/pnas.2007406117. Epub 2020 Sep 8. Proc Natl Acad Sci U S A. 2020. PMID: 32900920 Free PMC article.
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.
Dewald F, Pirkl M, Paluschinski M, Kühn J, Elsner C, Schulte B, Knüfer J, Ahmadov E, Schlotz M, Oral G, Bernhard M, Michael M, Luxenburger M, Andrée M, Hennies MT, Hafezi W, Müller MM, Kümpers P, Risse J, Kill C, Manegold RK, von Frantzki U, Richter E, Emmert D, Monzon-Posadas WO, Gräff I, Kogej M, Büning A, Baum M, Teipel F, Mochtarzadeh B, Wolff M, Gruell H, Di Cristanziano V, Burst V, Streeck H, Dittmer U, Ludwig S, Timm J, Klein F. Dewald F, et al. Nat Commun. 2023 May 19;14(1):2835. doi: 10.1038/s41467-023-38127-y. Nat Commun. 2023. PMID: 37208323 Free PMC article. Clinical Trial.
153 results